Eli Lilly says it could pull tens of millions of dollars invested in Australian clinical trials unless the federal government dramatically cuts the time it takes to put new drugs onto the Pharmaceutical Benefits Scheme.
The warning from one of the drugmaker’s top executives, visiting Australia this week, builds on pressure from the powerful pharmaceutical lobby for better deals for the medicines they sell domestically and comes at the same time as Donald Trump prepares to place tariffs on drug imports.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。